Cationic drugs and COVID-19 | Zendy

Oreste V. Brenna | Zendy; Sara Torretta | Zendy; Lorenzo Pignataro | Zendy; Federica Di Berardino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cationic drugs and COVID-19

Author(s) -

Oreste V. Brenna,

Sara Torretta,

Lorenzo Pignataro,

Federica Di Berardino

Publication year - 2020

Publication title -

international journal of immunopathology and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.724

H-Index - 53

eISSN - 2058-7384

pISSN - 0394-6320

DOI - 10.1177/2058738420966078

Subject(s) - cationic polymerization , covid-19 , pandemic , medicine , chemistry , virology , organic chemistry , disease , infectious disease (medical specialty) , outbreak

Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research